Member Info for chester18

Morning Drac

I'm so glad we've cheered you up a bit 😊

I do get your point Drac but let's not down play Vulpes £6m or £8m and Redmiles £44m ish. Those are huge investments and they are our gate-keepers. They know the true picture and the likely outcome and it didn't stop them taking their full allocation at the recent cash raise.

So it they are content then so am I. 👍

Van van

You are right about most of your comments. This has been a long road with many a false start. I’ve learnt so much along the way and the most important one is understanding what Scancell are trying to accomplish how that has evolved this past 10 years.

Fifteen years ago ‘Cancer Vaccine’ were two dirty words to big pharma. Ten years ago SCIB1 US Trials were stalled because the Ichor Tigrid inability to pass FDA approval. Five years ago the Pandemic threw several spanners in works.

But through progress in biotechnology the possibilities of a Cancer vaccine working have improved greatly. At the same time Scancell changed to the Pharma-Jet needle free delivery. That’s a bonus. iSCIB+ was brought through pre-clinical tests and approved for human trials.

So to say the least, it’s been a bit of a bumpy ride. However both Immunobody and Moditope are pioneering approaches to tackling cancer. Were are very deep into two trials that had to start with the worst case scenarios because they are new approaches.

“One day Rodders” we will see a RNS that states clearly that Scancell do have credible platforms and when that day arrives the SP will start its journey to what we think it’s worth.

Hopefully that idyllic set of circumstances will happen mid year 2025.

Ivy you must have missed my post from a few days ago, here’s the bit that addresses your question

“iSCIB+ cohort 4 Intradermal, is absolutely necessary because :

a ) the market is saying that it is potentially better that Intramusculer. So we need to have that data to compare.

b ) Scancell originally used the Ichor electroploration device which targeted the muscle cells so it was correct to continue with that delivery target when the move was made to the needle free Pharma Jet. If they had switch at that point to an Intradermal delivery there would have been no consistency in the ongoing data set for the SCOPE trial.

Also, time and energy is already being spent for the future development and manufacture of the iSCIB+ Vaccine. So the information already seen from cohort 3 must be as good or if not better than cohort 1.

In other words, they already know the direction they are taking for the Reg Trial and lets not forget the extra 15 years patent protection that brings with it”.

That leads to, what value could we put on the Immunobody platform if looked like it could become ‘Standard of Care’ ?

If the data arriving in 2025 is of high enough quality the possible bidding will begin in earnest….. very exciting times we would have

That means any Pharma co could partner with Scancell on the Reg Trial / Phase 3 / commercialisation.

I always thought we would be restricted to BMS. So that is another piece of opportunistic timing.

Here’s an interesting question if someone could answer :

The two checkpoints we are currently using both belong to Bristol Myers Squibb.

How long before both of those lose their patent protection and generics manufactured by ‘a.n.other’ can be used ?

I have just listened to to the presentation and come away feeling very positive about my investment. This is a different level of presentation, very factual, very determined and very confident that the results so far point clearly towards a commercial outcome.

Definitely feel we are 6 - 8 months from seeing Scancell becoming a disruptive force in the Oncology / Vaccine market. Obviously its the data that will ultimately drive that possibility but some of the details presented are very interesting.

iSCIB+ cohort 4 Intradermal, is absolutely necessary because :

a ) the market is saying that it is potentially better that Intramusculer. So we need to have that data to compare.

b ) Scancell originally used the Ichor electroploration device which targeted the muscle cells so it was correct to continue with that delivery target when the move was made to the needle free Pharma Jet. If they had switch at that point to an Intradermal delivery there would have been no consistency in the ongoing data set for the SCOPE trial.

Also, time and energy is already being spent for the future development and manufacture of the iSCIB+ Vaccine. So the information already seen from cohort 3 must be as good or if not better than cohort 1.

In other words, they already know the direction they are taking for the Reg Trial and lets not forget the extra 15 years patent protection that brings with it.

This list has been posted by me before but it’s relevant for what tomorrow’s RNS update may discuss.

SCIB1 + CPIs Fully Enrolled and Dosed

SCOPE Update on SCIB1 also including iSCIB+ Enrolled numbers for Cohort 3 ( Intramuscular ) and progress on Cohort 4 ( Intradermal ) especially the numbers achieved so far for HLA patients enrolled.

Modi1 Mono Update ( Ovarian, Renal, Breast and Head & Neck )

Modi1 plus Single Checkpoint ( Renal - Head& Neck )

Modi1 Neo-Adjuvant ( Trinity Delta report showed a table where 15 patients in the modi1 mono therapy was complete but No figure was given for Modi1 plus Checkpoint ). This Neo-Adjuvant setting must be very close to full enrolment and cohort completion.

Modi1 + 2CPI in RCC Early Toxicity Data should be relevant ( Trinity Delta reported that 7 patients had been dosed so far )

Plenty of clinical information will be at-hand if Scancell “feel that it should be shared at this time”.

Also, a little clarity on what potential partners are waiting to see or hear from Scancell would be very welcome.

🤞🤞

Hi Bioking

The information is there on the Scancell website under Share Information

Jean-Michel Cossery. 454,545 shares

Are we discussing the Chairman or the CEO ?

Just being pedantic as it matters, ‘not a jot’.

Lindy Durrant did answer the question of whether excellent data from SCIB1 plus Double Checkpoint would mean going ahead with the Reg Trial even though it only covers only 30 / 40% of Melanoma Cancer patients.

The answer was Yes, all the clinicians who know about the SCOPE trial said that the increase to 70% ORR means that it is still very important to push that forward.

How they would reconcile that with excellent data from the two iSCIB+ cohorts six months later, I don’t know.

As a very rough guide to the reporting of the completed cohorts :

SCIB1 plus Double Checkpoint will be around July / August.

iSCIB+ Double Checkpoint original Cohort October / November if they can fill the HLA - A2 places quickly.

iSCIB+ Double Checkpoint New Cohort probably January / February 2026, again it will hinge on suitable HLA - A2 patients being available.

The comparisons between cohorts cannot be accessed properly without the correct complement of HLA patients in each.

If Scancell ( Plus Partner ) do wait until they can chose a single cohort for the Registration Trial it may not get underway until late 2026.

It’s a puzzle that can only be resolved with the arrival of full and complete data sets.

It’s been a long road, from the ModiTope discovery to the first ModiFY patient being dosed.

I think we sometimes forget where the journey would be without Vulpes initial faith. Which ultimately lead to the game changing investment from Redmile.

SCOPE bubbled along in the back ground for years but is now the Key to having enough momentum to bring ModiTope through these early trial stages.

Repeating myself but it’s very important that we recognise that all the cohorts in our trials target late stage cancers. The hardest possible conditions to move the ORR needle by any significant amount. And Scancell are doing that.

Also Scancell is not a one trick pony, there are many multiples that can spring from these early trial successes.

We’re not guaranteed success but the clinical evidence we have so far still points to a very high probability.

Hi CrustyPete

I think we are looking at the same message about Modi1 in Head & Neck but filtering it in a different way.

I’m see it as progress in the trial, progress for that particular cohort and progress for those patients. To me it is very important news as it means Scancell’s tech is moving forward with every single piece of news.

I think you are interested in how the market sees the news that only 3 of 7 patients had their prognosis slightly improved. Obviously that is not going to push the SP very far.

I’m looking beyond the market turmoil and the fact that we have a seller that has no view on the future of Scancell, just how much they can accumulate from the holding they have. Someone pointed out that Calculus have a cost per share value of circa 5p. They have sold into every potential rise for the last six months or more.

So once that handbrake is off we should see the SP increase to a sensible price. It’s very frustrating but nothing we can do until they are completely out.

Your joining the dots would be even more probable if we receive a ModiFY trial update just prior to the JP Morgan.

In this instance it doesn’t because 3 out 7 provided enough evidence that Modi1 was effective enough to move the cohort forward.

7 patients with very little hope that they can see another 5 years and Modi1 has improved that possibility from 19% to 43%.

It doesn’t matter about the small sample size when you are dealing with the crushing prospects of a stage four cancer.

It’s a very significant step forward and means Scancell are now allowed to enrol up to 21 patients in the cohort. That is a huge result.

Thanks JB1

What we can guess at is that this seller is still making a small profit. Which if that’s the case it points to be Calculus being the villain.

I do find it strange that they cannot hook up with someone happy to take their stake at these reduced prices. Instead of continually suppressing Scancell’s value and their ability to raise funds higher than 10.5p.

These games are played well beyond my pay grade.

Here are some trial details that could be reported on in the Interim report.

SCIB1 + CPIs Fully Enrolled and Dosed ✔️

SCOPE Update on SCIB1 and also including iSCIB+ Enrolled numbers, especially in the HLA cohort.

Modi1 Mono Update ( Ovarian, Renal, Breast and Head & Neck )

Modi1 plus Single Checkpoint ( Renal - Head& Neck )

Modi1 Neo-Adjuvant ( TD said the 15 patients modi1 mono complete but No figure given for Modi1 plus Checkpoint )

Modi1 + 2CPI in RCC Early Safety Data ( TD said 7 patients dosed so far )

Plenty of clinical information will be at-hand if Scancell “feels that it should be shared at this time”.

Obviously as a shareholder who has participated in the last 4 cash calls, I would like to know as much as possible about how my investment is doing. 10p a Share is now ‘very derisory’ and we’re not getting any younger 🤔